Table 2.

Multivariable analysis for DFS for the total cohort and the KRASG12C group.

Group/variableaHR (95% CI)aP
Total cohort (N = 604)
 Primary tumor SUVmax1.03 (1.00–1.07)0.065
 DLCO0.99 (0.98–1.00)0.031
 LVI2.36 (1.43–3.91)0.001
 VPI1.66 (1.10–2.51)0.015
 STAS1.81 (1.02–3.23)0.044
 pStage
  IRef
  II or III1.80 (1.18–2.76)0.007
 KRAS mutation status
  Non-G12CRef
  Wild-type1.45 (0.85–2.47)0.2
  G12C1.84 (1.01–3.36)0.046
KRASG12C group (n = 95)
 LVI9.57 (2.20–41.54)0.003
 VPI2.25 (1.03–4.94)0.042
 Histologic subtype
  Lepidic, acinar, or papillaryRef
  Micropapillary or solid2.15 (0.95–4.87)0.067
  • Abbreviations: LVI, lymphovascular invasion; SUVmax, maximum standardized uptake value.

  • aMultivariable models for all factors were adjusted for pathologic stage.